Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Feb 14, 2020

SELL
$6.38 - $8.73 $4.21 Million - $5.76 Million
-660,000 Closed
0 $0
Q2 2019

Aug 13, 2019

SELL
$7.67 - $10.63 $1.15 Million - $1.59 Million
-150,000 Reduced 18.52%
660,000 $5.48 Million
Q1 2019

May 10, 2019

BUY
$7.58 - $9.94 $6.14 Million - $8.05 Million
810,000 New
810,000 $8.05 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $3.09B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Rubric Capital Management LP Portfolio

Follow Rubric Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Rubric Capital Management LP with notifications on news.